Misplaced Pages

Alirocumab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Jytdog (talk | contribs) at 20:23, 25 July 2015 (Side effects: add start of pharmacology). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 20:23, 25 July 2015 by Jytdog (talk | contribs) (Side effects: add start of pharmacology)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
page is in the middle of an expansion or major revampingThis article or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days, please remove this template.
If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use. This article was last edited by Jytdog (talk | contribs) 9 years ago. (Update timer)
Pharmaceutical compound
Alirocumab
Monoclonal antibody
Type?
SourceHuman
TargetProprotein convertase subtilisin/kexin type 9 (PCSK9)
Clinical data
Trade namesPraluent
Routes of
administration
Subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
Chemical and physical data
FormulaC6472H9996N1736O2032S42
Molar mass146.0 kDa g·mol

Alirocumab (trade name Praluent) is a human monoclonal antibody PCSK9 inhibitor biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment of hypercholesterolemia for adults whose cholesterol is not controlled by diet and statin treatment. It is also known as REGN727 and SAR236553.

Medical uses

Alirocumab is used as a second line treatment to lower LDL cholesterol for people who have hereditary high cholesterol and people with atherosclerosis who require additional lowering of LDL cholesterol when diet and statin treatment have not worked. It is administered by injection.

Side effects

Side effects that occurred in more than 2% of people treated with in clinical trials and that occurred more frequently than with placebo, included nose and throat irritation, injection site reactions and bruising, flu, urinary tract infection, diarrhea, bronchitis and cough, and muscle pain, soreness, and spasms.

Pharmacology

Main article: PCSK9

Alirocumab works by inhibiting the PCSK9. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), which leads to the receptor being degraded, and thus less LDL cholesterol being removed from circulation. Inhibiting PCSK9 prevents the LDLR from being degraded, and thus promotes removal of LDL cholesterol from circulation.

Physical and chemical properties

History

It was discovered by Regeneron Pharmaceuticals and is being co-developed with Sanofi. A main competitor in the race to worldwide health authority approval is evolocumab in development by Amgen.

In July 2015, the FDA approved alirocumab as a second line treatment to lower LDL cholesterol for people who have hereditary high cholesterol and people with atherosclerosis who require additional lowering of LDL cholesterol when diet and statin treatment have not worked. This was the first approval of a PCSK9 inhibitor.

References

  1. International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization
  2. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 24316621, please use {{cite journal}} with |pmid=24316621 instead.
  3. ^ Alirocumab label Label revised, July 2015. Page accessed July 25, 2015
  4. *"The Evolving Role of PCSK9 Modulation in the Regulation of LDL-Cholesterol". Retrieved 13 May 2015.
  5. ^ FDA. July 24, 2015 FDA Press release: FDA approves Praluent to treat certain patients with high cholesterol
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone
Human
Humanized
Musculoskeletal
Human
Circulatory
Human
Mouse
Chimeric
Humanized
Neurologic
Human
Humanized
Angiogenesis inhibitor
Humanized
Growth factor
Human
Humanized
Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: